Innovent Biologics Gains China Approval for TABOSUN and Sintilimab in Colon Cancer Neoadjuvant Therapy
I'm PortAI, I can summarize articles.
Innovent Biologics Inc. has received approval from China's National Medical Products Administration for TABOSUN® and sintilimab as neoadjuvant therapy for certain colon cancers. The approval is based on the NeoShot trial, which showed an 82% pathological complete response rate among the first 50 patients treated, with no significant safety risks compared to direct surgery.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments